Clinical Trials Logo

Clinical Trial Summary

Hip fracture posed a major challenge to the health care system, with the one-year mortality of hip fracture reported as being approximately 20%. Perioperative haemoglobin level was associated with functional level of the patient and even mortality.

Different methods for administration of tranexamic acid had been described. It was well established that systemic administration of tranexamic acid could reduce perioperative blood loss and transfusion rate. Topical administration had been shown to decrease blood loss and transfusion rate.

The objective of our study is to investigate the hypothesis that tranexamic acid will reduce blood loss and transfusion rate in elderly patients undergoing hip fracture surgery.


Clinical Trial Description

The incidence of geriatric hip fractures is projected to increase by more than 250% in the next twenty-five years as the world population ages. Hip fracture in elderly patients are associated with significant morbidity and mortality. One of the significant morbidity is blood loss, which has been reported as high as 1500ml. Blood loss may lead subsequent blood transfusion. The rate of blood transfusion has been reported between 20 to 60%. Blood loss and subsequent blood transfusion could lengthen the overall hospital length of stay and delay the rehabilitation.

Tranexamic acid, one of antifibrinolytic agents, is a synthetic derivative of the amino acid lysine and acts as a competitive inhibitor in the activation of plasminogen to plasmin, therefore preventing the degradation of fibrin. Shakur et al. reported that the use could reduce mortality in trauma patients. Tranexamic acid has been widely used in elective orthopaedic surgery such as total joint replacement and spine surgery. Several authors reported that tranexamic acid could decreases the blood loss, transfusion rate and cost. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04290884
Study type Interventional
Source The University of Hong Kong
Contact
Status Active, not recruiting
Phase Phase 4
Start date May 23, 2018
Completion date May 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05134805 - Outcomes of Hemiarthroplasty Versus Cephalo-medullary Fixation to Treat Unstable Intertrochanteric Femoral Fractures N/A
Recruiting NCT05669040 - mHealth to Improve the Experience, Adherence to Drug Treatment and Positive Mental Health N/A
Not yet recruiting NCT06400732 - Post Market Evaluation of Clinical Safety and Performance of the Fitbone Transport and Lengthening System
Recruiting NCT06018610 - Effectiveness of Relaxation and Massage Methods in Proximal Femur Fractures N/A
Recruiting NCT04299022 - Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
Terminated NCT02826538 - 3D Geplante Osteosynthesen Mit Patientenspezifischen Zielvorrichtungen N/A
Not yet recruiting NCT05736016 - Medial Wedge Insoles to Improve Gait in Persons After Total Hip Replacement N/A